Therapies based on principles of ocular immune privilege

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 317-327

  Zhang Hoover, Jie ^a   Stein Streilein, Joan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA2; DIFFERENTIATION ANTIGEN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALLERGIC PNEUMONITIS; ANTERIOR EYE CHAMBER; ANTIGEN PRESENTING CELL; ASTHMA; CELLULAR IMMUNITY; CORNEA TRANSPLANTATION; FIBROSING ALVEOLITIS; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VIVO STUDY; INOCULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL; UVEITIS; ANIMAL; EYE; IMMUNOLOGY; LUNG FIBROSIS; PHYSIOLOGY;

ANIMALS; ANTERIOR CHAMBER; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION; ASTHMA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EYE; HUMANS; IMMUNE TOLERANCE; PULMONARY FIBROSIS; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA2;

EID: 33947499854     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099281     Document Type: Review

References (55)

1. Kaplan HJ, Streilein JW: Do immunologically privileged sites require a functioning spleen? Nature 1974;251:553-554.
2. Kaplan HJ, Streilein JW, Stevens TR: Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells. J Immunol 1975;118:809-814.
3. Kaplan HJ, Streilein JW: Immune response to immunization via the anterior chamber of the eye. I. F1-lymphocyte-induced immune deviation. J Immunol 1977;118:809-814.
4. Kaplan HJ, Streilein JW: Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. J Immunol 1978;120:689-693.
5. Niederkorn J, Streilein JW, Shadduck JA: Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci 1980;20:355-363.
6. Streilein JW, Niederkorn JY: Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med 1981;153:1058-1067.
7. Niederkorn JY, Streilein JW: Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed type hypersensitivity but normal cytotoxic T lymphocyte responses. J Immunol 1983;131:2670-2674.
8. Streilein JW, Niederkorn JY: Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J Immunol 1985;134:1381-1387.
9. Niederkorn JY, Mellon J: Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996;37:2700-2707.
10. Sonoda A, Sonoda Y, Muramatu R, Streilein JW, Usui M: ACAID induced by allogeneic corneal tissue promotes subsequent survival of orthotopic corneal grafts. Invest Ophthalmol Vis Sci 2000;41:790-798.
11. Sonoda Y, Streilein JW: Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. Immunology 1993;150:1727-1734.
12. Sonoda Y, Sano Y, Ksander B, Streilein JW: Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 1995;36:427-434.
13. Streilein JW: Immunobiology and immunopathology of corneal transplantation; in Streilein JW (ed): Immune Response and the Eye. Chem Immunol. Basel, Karger, 1999, vol 73, pp 186-206.
14. Hara Y, Caspi RR, Wiggert B, Chan CC, Wilbanks GA, Streilein JW: Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein. J Immunol 1992;148:1685-1692.
15. Mizuno K, Altman NF, Clark AF, Streilein JW: Histopathologic analysis of experimental autoimmune uveitis attenuated by intracameral injection of S-antigen. Curr Eye Res 1989;8:113-121.
16. Hara Y, Caspi RR, Wiggert B, Dorf M, Streilein JW: Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J Immunol 1992;149:1531-1538.
17. Cousins SW, McCabe MM, Danielpour D, Streilein JW: Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991;32:2201-2211.
18. Hara Y, Okamoto S, Rouse B, Streilein JW: Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type. J Immunol 1993;151:5162-5171.
19. Kezuka T, Streilein JW: In vitro generation of regulatory CD8T cells similar to those found in mice with anterior chamber associated immune deviation. Invest Ophthalmol Vis Sci 2000;41: 1803-1811.
20. Kezuka T, Streilein JW: Analysis of in vivo regulatory properties of T cells activated in vitro by TGFβ2-treated antigen presenting cells. Invest Ophthalmol Vis Sci 2000;41:1410-1421.
21. Wilbanks GA, Mammolenti M, Streilein JW: Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 1992;22:165-173.
22. Wilbanks GA, Mammolenti M, Streilein JW: Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID. J Immunol 1991;146:3018-3024.
23. Wilbanks GA, Streilein JW: Studies on the induction of anterior chamber-associated immune deviation (ACAID). I. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991;146:2610-2617.
24. Wilbanks GA, Streilein JW: Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-beta. Eur J Immunol 1992;22:1031-1036.
25. Wilbanks GA, Streilein JW: Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of tw o functionally and phenotypically distinct T-suppressor cell populations. Immunology 1990;71:383-389.
26. Kosiewicz MM, Okamoto S, Miki S, Ksander BR, Shimizu T, Streilein JW: Imposing deviant immunity on the presensitized state. J Immunol 1994;153:2962-2973.
27. Wilbanks GA, Streilein JW: Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties. Reg Immunol 1992;4: 130-137.
28. Niederkorn JY, Mayhew E: Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Eur J Immunol 1995;25:2783-2787.
29. Faunce DE, Sonoda KH, Stein-Streilein J: MIP-2 recruits NKT cells to the spleen during tolerance induction. J Immunol 2001;166:313-321.
30. D'Orazio TJ, Niederkorn JY: Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology 1998;95:47-55.
31. Skelsey ME, Mayhew E, Niederkorn JY: Splenic B cells act as antigen presenting cells for the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 2003;44: 5242-5251.
32. D'Orazio TJ, Mayhew E, Niederkorn JY: Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J Immunol 2001;166:26-32.
33. Sonoda KH, Stein-Streilein J: CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur J Immunol 2002;32:848-857.
34. Lutz MB, Schuler G: Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Immunol 2002;23:445-449.
35. Rutella S, Lemoli RM: Regulatory T cells and tolerogenic dendritic cells: From basic biology to clinical applications. Immunol Lett 2004;94:11-26.
36. Bilsborough J, George TC, Norment A, Viney JL: Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 2003;108:481-492.
37. Akbari O, DeKruyff R, Umetsu D: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2:725-731.
38. Dhodapkar M, Steinman R, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
39. Groux H, Fournier N, Cottrez F: Role of dendritic cells in the generation of regulatory T cells. Semin Immunol 2004;16:99-106.
40. Adorini L, Giarratana N, Penna G: Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004;16:127-134.
41. Kuchroo VK, Minami M, Diamond B, Dorf ME: Functional analysis of cloned macrophage hybridomas. VI. Differential ability to induce immunity or suppression. J Immunol 1988;141: 10-16.
42. Masli S, Turpie B, Hecker KH, Streilein JW: Expression of thrombospondin in TGFß-treated APCs and its relevance to their immune deviation-promoting properties. J Immunol 2002;168: 2264-2273.
43. Zhang-Hoover J, Stein-Streilein J: Tolerogenic APC generate CD8+ regulatory cells that modulate pulmonary interstitial fibrosis. J Immunol 2004;172:178-185.
44. Katagiri K, Zhang-Hoover J, Mo JS, Stein-Streilein J, Streilein JW: Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology. J Immunol 2002;169:84-89.
45. Zhang-Hoover J, Finn P, Stein-Streilein J: Modulation of ovalbumin-induced airway inflammation and hyperactivity by tolerogenic APC. J Immunol 2005;175:7117-7124.
46. Kosiewicz MM, Alard P, Liang S, Clark SL: Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand. Int Immunol 2004;16:697-706.
47. Keino H, Masli S, Sasaki S, Streilen JW, Stein-Streilein J: CD8+ T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance. Invest Ophthalmol Vis Sci 2006;47:1533-1542.
48. Gordon JR, Li F, Nayyar A, Xiang J, Zhang X: CD8α+, but not CD8α-, dentric cells tolerize Th2 responses via contact-dependent and -independent mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a mouse model of asthma. J Immunol 2005;175: 1516-1522.
49. Okamoto S, Kosiewicz MM, Caspi RR, Streilein JW: ACAID as a potential therapy for established experimental autoimmune uveitis; in Nussenblatt RB, Whitcup SM, Caspi RR, Gery I (eds): Advances in Ocular Immunology Amsterdam, Elsevier, 1994, pp 195-198.
50. Streilein JW: OculaT immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003;74:179-185.
51. Faunce DI, Terajewicz A, Stein-Streilein J: Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J Immunol 2004;172:1991-1995.
52. Nakamura T, Terajewicz A, Stein-Streilein J: Mechanisms of peripheral tolerance following intracameral inoculation are independent of IL-13 or ST AT6. J Immunol 2005;175:2643-2646.
53. Kosiewicz MM, Streilein JW: Is deviant immunity induced by intraocular injection of antigen dependent on Th2 cells? Invest Ophthalmol Vis Sci 1996;37:S1136.
54. Streilein JW: OculaT immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:878-889.
55. Kezuka T, Sakai JI, Usui N, Streilein JW, Usui M: Evidence for antigen-specific immune deviation in patients with acute retinal necrosis. Arch Ophthalmol 2001;119:1044-1049.